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The success of chemotherapy for metastatic germ cell
tumours has led to them being described as the model of a
curable malignancy. However, 20-30% of patients with
metastatic disease relapse after first-line chemotherapy, and
for them the prognosis is poor (Loehrer et al., 1986; Motzer
et al., 1991; Pizzocaro et al., 1992a; Horwich et al., 1993a:
Josefsen et al., 1993). High-risk patients can often be
identified from the extent of disease at presentation. Of 7%
patients contributing to prognostic model analyses at the
Memorial Hospital, 73% were predicted to be in remission 1
year after chemotherapy. This figure fell to 30% in patients
identified as being in a poor-risk category (Bajorin et al.,
1994). Similarly, in an Eastern Cooperative Oncology Group
(ECOG) chemotherapy trial based on patients categorised as
having advanced disease on the Indiana University
classification, less than 50% remained continuously disease
free (Loehrer et al., 1993). These figures indicate a substantial
need to improve the efficacy of chemotherapy in some sub-
groups of patients with metastatic germ cell tumours, and
increasing the dose intensity of conventional agents has yet
to have a demonstrable impact on their survival (Nichols et
al., 1991; Droz et al., 1992). Therefore, there is a continued
need for drug development in germ cell tumours, and current
examples include the phase II investigation of Taxol (Motzer
et al., 1994) as well as the observations reported by Pera et
al. (1995) in this issue, both of which merit more extensive
investigation. Even patients who have failed on previous
chemotherapy usually retain an excellent performance status
and good bone marrow function, and the poor prognosis
justifies innovative approaches to their treatment (Horwich et
al., 1993b).
One of the difficulties in evaluating results of new ap-
proaches to the salvage treatment of germ cell tumours is the
heterogeneity of patients at this phase of the illness. Relevant
factors which might influence prognosis include the extent of
disease at presentation, the details and response to primary
chemotherapy, together with residual organ tolerance, espec-
ially renal function, the disease-free interval before progres-
sion and the extent of disease at relapse (Horwich et al.,
1993a; Josefsen et al., 1993). Patients referred to a specialty
centre may have previously suffered a number of recurrences
after a range of conventional chemotherapy approaches,
whereas those treated initially at the specialty centre may
enter an experimental programme after their first chemo-
therapy course, i.e. after only four prior chemotherapy cycles
(Hutter et al., 1994). In a series of 105 patients treated for
relapse at the Royal Marsden Hospital between 1980 and
1988 (Horwich et al., 1993b) the stage of disease at relapse
was stage I marker positive in six patients, stage II in 17
patients, stage III in nine patients and stage IV in 73 patients
and, using the Medical Research Council definition of disease
bulk (MRC, 1985), the volume of relapse was 'small' in 42
patients, 'large' in 14 patients and 'very large' in 49 patients.
Fewer of these patients had high markers (alphafetoprotein
> 1000 units 1-1 or human chonronic gonadotrophin
>10,000 units -') at the time of relapse than at original
presentation, namely 21% vs 37% respectively. The interval
between the end of initial chemotherapy and relapse was
between 0 and 8 months in 30 patients, between 8 and 15
months in 48 patients and more than 15 months in 27
patients. Of the total series, the 3 year survival probability
from time of beginning salvage chemotherapy was 30%.
However, a multivariate analysis of survival showed a
significantly higher risk of mortality in those with a disease-
free interval of less than 8 months and in those with very
large volume disease at relapse. The analysis allowed sub-
groups to be identified whose prognosis on standard-dose
chemotherapy was extremely poor with a 3 year survival
probability of less than 10%, while other subgroups had a 3
year survival probability of up to 70%, suggesting that high-
risk salvage therapies might be employed on a selective basis.
Similarly, a series of 55 patients reported from Norway had a
disease-free survival from the time of salvage chemotherapy
of 27% at 5 years. A better prognosis was defined by com-
plete response to primary treatment lasting more than 6
months, and this subgroup had a 45% 5 year disease-free
survival probability (Josefsen et al., 1993).
Therapeutic approaches to be considered in salvage
therapy include the use of alternative drug combinations, the
use of local treatment modalities such as surgery or radiation
therapy and the role of high-dose chemotherapy with stem
cell support. The appropriate deployment of these options is
influenced by the primary chemotherapy and initial response
but also by current treatment tolerance and the extent of
disease at relapse. The likelihood of the relapse being
associated with a degree of drug resistance encourages an
aggressive surgical approach for disease which is relatively
localised although, unless the relapse is both isolated and
indolent, salvage therapy should be initiated with chemo-
therapy. Assessments should include the glomerular filtration
rate in those who have previously had cisplatin and lung
function tests in those who have had bleomycin. Staging
should include CT or MRI scan of the brain (Josefsen et al.,
1993; Raina et al., 1993).
There is some evidence that alternative standard chemo-
therapy regimens can cure a proportion of patients in whom
primary chemotherapy has failed. Etoposide showed
significant activity in patients who had relapsed after the
combination of platinum, vinblastine and bleomycin (PVB)
(Fitzharris et al., 1980), and the combination of etoposide
and cisplatin was curative in approximately one-quarter of
patients (Bosl et al., 1985; Hainsworth et al., 1985). It was
more difficult to salvage patients whose primary chemo-
therapy contained etoposide and cisplatin (Horwich and
Peckham, 1984). However, ifosfamide was highly active in
this context (Wheeler et al., 1986) and long-term remissions
were obtained with this drug in combination with cisplatin
and either etoposide or vinblastine (Loehrer et al., 1986;
Einhorn et al., 1990; Harstrick et al., 1991; Pizzocaro et al.,
1992b). Complete response in these series was uncommon in
those who had had an unfavourable response to initial
chemotherapy. Other standard drugs have been disappointing
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in patients in whom cisplatin therapy has failed (Atkinson et
al., 1987), except that Levi et al. (1990) reported that the
combination of etoposide, dactinomycin and methotrexate
achieved some long-term remissions in patients who had
previously failed to respond to platinum, vinblastine and
bleomycin. Daily oral etoposide cycles lasting 21 days at a
dose of 50mgm-2 day-', orally, have been employed in
patients who failed to respond to combination chemotherapy
with a modest number of prolonged responses (Cantwell et
al., 1990; Miller and Einhorn, 1990). More recently, Taxol
has been investigated in patients who had failed to respond
to standard platinum therapies and shows promising activity
(Motzer et al., 1994). Of 31 patients who had progressed
after a median of four previous cycles of platinum-based
chemotherapy, eight responded and two remained free from
any signs of progressive disease for 13+ and 14+ months.
This was a single-agent study based on Taxol at doses
between 250 and 300mgm2 given as a 24h infusion once
every 3 weeks. This result will lead to studies combining
Taxol with cisplatin.
Salvage surgery has an important role in the consolidation
of salvage chemotherapy response in patients with localised
relapse. In a series of 49 patients whose salvage included
surgery, a 5 year survival probability of 50% was achieved
(Hendry et al., 1993). When residual tumour is small, local-
ised but inoperable, radiation doses of between 40 and 45 Gy
in 20-25 fractions are usually effective (Lampe et al., 1995).
In some patients with an indolent pattern of disease and a
sequence ofrelatively localised relapses, a series ofoperations
may be indicated. Best results are obtained when disease has
been confined to the retroperitoneum (Murphy et al., 1993).
In this context, surgery usually leads to resection of masses
containing viable undifferentiated tumour and, despite the
achievement of complete remission, further chemotherapy
should be considered (Fox et al., 1993). Daily oral etoposide
has been investigated in this role (Cooper et al., 1994).
The relatively low success rate of salvage chemotherapy in
patients who have failed to respond to etoposide-cisplatin
combinations has led to preliminary evaluations of high-dose
chemotherapy with autologous bone marrow transplant
(ABMT) or, more recently, blood stem cell support. In view
of the non-haematological toxicities of cisplatin, high-dose
therapy is usually based on carboplatin, together with
etoposide and either cyclophosphamide or ifosfamide. Trials
of this approach were begun in Indiana University in 1986
using high-dose carboplatin and etoposide with ABMT. Of
32 patients registered for this study in the first 2 years, the
chemotherapy consisted of etoposide 1200mgm-2 together
with carboplatin in an escalating dose schedule from 900 mg
m-2 to 2000 mgm-2. Seven patients died oftreatment-related
problems. However, there were eight complete remissions in
a 42% response rate (Nichols et al., 1989). More recent
follow-up of the first 40 patients treated in this same study
found that only six (15%) were alive and continuously
disease free at a minimum of 36 months, though a further
patient had died of acute myelogenous leukaemia while in
remission 28 months after ABMT (Broun et al., 1992). A
recent review of high-dose chemotherapy suggested that the
inclusion of either cyclophosphamide or ifosfamide in the
high-dose regimen may increase the proportion of patients
with a durable complete remission (Motzer and Bosl, 1992),
and this was supported by multivariate analysis of a series
from France (Droz et al., 1993). The review included 272
patients reported since 1984 who had been treated with
high-dose chemotherapy and ABMT for relapse of germ cell
tumour after cisplatin chemotherapy. There were 80 complete
responses (31%), but only 44 of these (17%) were durable,
and in the same series there were 29 (11%) treatment-related
deaths. However, excellent results have also been reported
using only carboplatin and etoposide in the high-dose regi-
men (Broun et al., 1994). The addition of an alkylating agent
to the high-dose chemotherapy combination does not appear
to increase treatment-related mortality (Siegert et al., 1991;
Motzer et al., 1992; Linkesch et al., 1993). Careful patient
selection associated with the use of growth factors and blood
stem cells can reduce the toxicity.
At the Royal Marsden Hospital, our treatment approach
for patients who have failed standard schedules of cisplatin-
based chemotherapy is to undertake a 4 week course of
intensive weekly induction based on bleomycin, vincristine
and cisplatin (Horwich et al., 1993b). Patients whose disease
stabilised or responded to this went on to high-dose carbo-
platin and etoposide and, if the response continued, a second
cycle of high-dose carboplatin and etoposide was admini-
stered 2-3 months later. The high-dose chemotherapy was
supported by autologous bone marrow transplantation.
Thirty-three patients were eligible for this treatment pro-
gramme between 1991 and 1993, but three declined the high-
dose approach and, of the remaining 30, seven progressed
during conventional dose induction chemotherapy (Lampe et
al., 1995). A fixed dose of etoposide at 1200mgm-2 was
employed in each high-dose course. However, the carboplatin
dose was based on renal function to achieve a desired serum
concentration x time (Calvert et al., 1989). The carboplatin
dose was increased from 15 mg ml-' min to 40 mgmlV- min
and, based on a range oftoxicities, but especially gastrointes-
tinal toxicity, it was recommended that further studies be
pursued at a serum concentration x time of 30 mgmnl ' min.
Eight of the 23 patients treated with high-dose chemotherapy
are alive and in remission 6-32 months from start of salvage
chemotherapy.
The range ofresults in patients whose salvage chemotherapy
is based on high-dose chemotherapy, together with the heter-
ogeneity of treated patients, has made it difficult to evaluate
the true role of this approach. There is little doubt that some
patients progressing on standard dose chemotherapy can
achieve long-term complete remission using high-dose techni-
ques, but a higher proportion of remissions are obtained in
patients who remain sensitive to standard dose treatment,
who have a limited extent of disease at relapse and whose
initial treatment may have been less dose intensive (Barnett et
al., 1991; Einhorn, 1994). The technique is costly, in terms of
both financial resources and patient morbidity, and the role
ofhigh-dose salvage is now being evaluated rigorously within
the context of a prospective randomised trial in patients who
have progresed following initial platinum-based chemo-
therapy. The trial is coordinated by JL Pico of the Bone
Marrow Transplantation Unit in the Institut Gustave Roussy
and is under the auspices of the European Bone Marrow
Transplant Group. Four cycles of the combination of cis-
platin, ifosfainide and either etoposide or vinblastine are
compared with three cycles of these drugs followed by high-
dose carbopec (carboplatin, etoposide and cyclophospha-
mide). The trial opened in 1993 and is seeking a total of 280
patients based on the need to demonstrate a 15% difference
in 1 year survival. This trial addresses an important question
and merits support from those involved in the treatment of
germ cell tumours.
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